152 related articles for article (PubMed ID: 14623059)
1. Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapy.
Eekhoff ME; Zwinderman AH; Haverkort DM; Cremers SC; Hamdy NA; Papapoulos SE
Bone; 2003 Nov; 33(5):831-8. PubMed ID: 14623059
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of Paget's disease with olpadronate. Its efficacy in partial responders to oral pamidronate].
González D; Pastrana M; Mautalen C
Medicina (B Aires); 1997; 57 Suppl 1():25-31. PubMed ID: 9567351
[TBL] [Abstract][Full Text] [Related]
3. Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: a 2-year study.
Gutteridge DH; Retallack RW; Ward LC; Stuckey BG; Stewart GO; Prince RL; Kent GN; Bhagat CI; Price RI; Thompson RI; Nicholson GC
Bone; 1996 Oct; 19(4):387-94. PubMed ID: 8894145
[TBL] [Abstract][Full Text] [Related]
4. Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone.
Cremers SC; Eekhoff ME; Den Hartigh J; Hamdy NA; Vermeij P; Papapoulos SE
J Bone Miner Res; 2003 May; 18(5):868-75. PubMed ID: 12733726
[TBL] [Abstract][Full Text] [Related]
5. Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD).
Harinck HI; Papapoulos SE; Blanksma HJ; Moolenaar AJ; Vermeij P; Bijvoet OL
Br Med J (Clin Res Ed); 1987 Nov; 295(6609):1301-5. PubMed ID: 3120987
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates for Paget's disease of bone in adults.
Corral-Gudino L; Tan AJ; Del Pino-Montes J; Ralston SH
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD004956. PubMed ID: 29192423
[TBL] [Abstract][Full Text] [Related]
7. Short-term therapy with oral olpadronate in active Paget's disease of bone.
González DC; Mautalen CA
J Bone Miner Res; 1999 Dec; 14(12):2042-7. PubMed ID: 10620063
[TBL] [Abstract][Full Text] [Related]
8. Paget's disease of bone: benefits of neridonate as a first treatment and in cases of relapse after clodronate.
Filipponi P; Cristallini S; Policani G; Casciari C; Gregorio F
Bone; 1998 Dec; 23(6):543-8. PubMed ID: 9855463
[TBL] [Abstract][Full Text] [Related]
9. Intravenously administered pamidronate in the treatment of Paget's disease of bone.
Tucci JR; Bontha S
Endocr Pract; 2001; 7(6):423-9. PubMed ID: 11747277
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate.
Adami S; Salvagno G; Guarrera G; Montesanti F; Garavelli S; Rosini S; Lo Cascio V
Calcif Tissue Int; 1986 Oct; 39(4):226-9. PubMed ID: 2947663
[TBL] [Abstract][Full Text] [Related]
11. Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate.
Schweitzer DH; Zwinderman AH; Vermeij P; Bijvoet OL; Papapoulos SE
J Bone Miner Res; 1993 Feb; 8(2):175-82. PubMed ID: 8442435
[TBL] [Abstract][Full Text] [Related]
12. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
[TBL] [Abstract][Full Text] [Related]
13. Low dose intravenous 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) for the treatment of Paget's disease of bone.
Cantrill JA; Buckler HM; Anderson DC
Ann Rheum Dis; 1986 Dec; 45(12):1012-8. PubMed ID: 3813665
[TBL] [Abstract][Full Text] [Related]
14. Short-term intravenous therapy with Neridronate in Paget's disease.
Adami S; Bevilacqua M; Broggini M; Filipponi P; Ortolani S; Palummeri E; Ulivieri F; Nannipieri F; Braga V
Clin Exp Rheumatol; 2002; 20(1):55-8. PubMed ID: 11892710
[TBL] [Abstract][Full Text] [Related]
15. A single infusion of bisphosphonate AHPrBP in the treatment of Paget's disease of bone.
Chakravarty K; Merry P; Scott DG
J Rheumatol; 1994 Nov; 21(11):2118-21. PubMed ID: 7869320
[TBL] [Abstract][Full Text] [Related]
16. Changes in serum HDL and LDL cholesterol in patients with Paget's bone disease treated with pamidronate.
Montagnani A; Gonnelli S; Cepollaro C; Campagna MS; Franci MB; Pacini S; Gennari C
Bone; 2003 Jan; 32(1):15-9. PubMed ID: 12584031
[TBL] [Abstract][Full Text] [Related]
17. A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone.
Thiébaud D; Jaeger P; Gobelet C; Jacquet AF; Burckhardt P
Am J Med; 1988 Aug; 85(2):207-12. PubMed ID: 3261129
[TBL] [Abstract][Full Text] [Related]
18. Determinants of remission of Paget's disease of bone.
Patel S; Stone MD; Coupland C; Hosking DJ
J Bone Miner Res; 1993 Dec; 8(12):1467-73. PubMed ID: 8304048
[TBL] [Abstract][Full Text] [Related]
19. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission.
Stuckey BG; Lim EM; Kent GN; Ward LC; Gutteridge DH
J Bone Miner Res; 2001 Sep; 16(9):1719-23. PubMed ID: 11547843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
